Amydis Announces Enrollment of Cerebral Amyloid Angiopathy Participants in Phase 1/2a Retinal Tracer Trial
21 févr. 2023 05h00 HE
|
Amydis, Inc.
SAN DIEGO, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Amydis Inc., a privately held clinical-stage company pioneering a platform of ocular tracers that enable imaging of disease biomarkers in the eye, today...
Amydis Receives NIH Grant Award to Develop a Novel Tau Retinal Tracer for Alzheimer's Diseases and other Tauopathies
02 sept. 2021 07h00 HE
|
Amydis, Inc.
SAN DIEGO, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Amydis Inc., a leading ocular tracer pharmaceutical company with a broad portfolio of diagnostic drug candidates targeting CNS biomarkers in the eye,...
Amydis Receives $3 Million NIH Commercialization Readiness Pilot Grant Award for Novel Amyloid Beta Retinal Tracer in Cerebral Amyloid Angiopathy
28 juin 2021 07h00 HE
|
Amydis, Inc.
SAN DIEGO, June 28, 2021 (GLOBE NEWSWIRE) -- Amydis Inc., a leading ocular tracer pharmaceutical company with a broad portfolio of diagnostic drug candidates targeting CNS biomarkers in the eye,...
Amydis Announces Successful Completion of Pre-IND Meeting with the FDA for the Development of AMDX-2011P, a First-in-Class Retinal Tracer for the Diagnosis of Amyloid Angiopathy
11 janv. 2021 07h00 HE
|
Amydis, Inc.
SAN DIEGO, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Amydis Inc., a leading ocular tracer pharmaceutical company with a broad portfolio of diagnostic drug candidates targeting CNS biomarkers in the eye,...
Amydis Awarded NIH Ph2A Grant for Cerebral Amyloid Angiopathy
23 sept. 2019 07h00 HE
|
Amydis, Inc.
SAN DIEGO, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Amydis, Inc., a privately-held pharmaceutical company developing proprietary drugs to detect, monitor, and screen for amyloid-related diseases,...
Optos and Amydis Establish Clinical Alliance to Develop Early Diagnostic Test for Alzheimer’s Disease
24 oct. 2018 07h00 HE
|
Amydis, Inc.
LOS ANGELES, Oct. 24, 2018 (GLOBE NEWSWIRE) -- Optos Plc, a subsidiary of Nikon Corporation, Japan, and Amydis, Inc. today announced a clinical alliance focused on the development of an eye test by...
IGC Announces Results of Annual Shareholders Meeting
13 nov. 2017 14h22 HE
|
India Globalization Capital
BETHESDA, Md., Nov. 13, 2017 (GLOBE NEWSWIRE) -- India Globalization Capital, Inc. (NYSE American:IGC), announced that during its 2016-2017 Annual Meeting of Shareholders scheduled for, and convened...
IGC-AD1 Targeting Alzheimer’s Disease to be commercialized in early 2018 Through Medical Dispensaries
18 oct. 2017 08h00 HE
|
India Globalization Capital
BETHESDA, Md., Oct. 18, 2017 (GLOBE NEWSWIRE) -- India Globalization Capital, Inc. (NYSE-MKT:IGC) provides compelling in vitro data compiled from genetically engineered cell lines within an...
IGC Prepares a Liquid Delivery Formulation of IGC-AD1 for Alzheimer’s Based on Novel In Vitro Data
04 oct. 2017 08h00 HE
|
India Globalization Capital
BETHESDA, Md., Oct. 04, 2017 (GLOBE NEWSWIRE) -- India Globalization Capital, Inc. (NYSE-MKT:IGC) provides an update on compelling in vitro data compiled from genetically engineered cell lines...
IGC Builds Team Adding Industry Leader Dr. Chuanhai Cao, an expert on THC-Based Alzheimer’s Disease Treatments
01 août 2017 08h41 HE
|
India Globalization Capital
BETHESDA, Md., Aug. 01, 2017 (GLOBE NEWSWIRE) -- India Globalization Capital, Inc. (NYSE-MKT:IGC) is pleased to announce that Dr. Chuanhai Cao has joined its medical research team as a key Advisor. ...